S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
NASDAQ:ACET

Adicet Bio (ACET) Stock Forecast, Price & News

$5.48
-0.13 (-2.32%)
(As of 05/31/2023 ET)
Compare
Today's Range
$5.40
$5.72
50-Day Range
$5.27
$7.13
52-Week Range
$5.13
$21.87
Volume
785,671 shs
Average Volume
478,014 shs
Market Capitalization
$235.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.40

Adicet Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
398.2% Upside
$27.40 Price Target
Short Interest
Healthy
9.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.15mentions of Adicet Bio in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.18) to ($2.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

489th out of 1,006 stocks

Pharmaceutical Preparations Industry

236th out of 492 stocks


ACET stock logo

About Adicet Bio (NASDAQ:ACET) Stock

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf“ gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Receive ACET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.

ACET Stock News Headlines

Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty
A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.
Adicet Bio (NASDAQ:ACET) Coverage Initiated at StockNews.com
H.C. Wainwright Reaffirms Their Buy Rating on Adicet Bio (ACET)
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
JMP Securities Sticks to Their Buy Rating for Adicet Bio (ACET)
Adicet Bio (ACET) to Release Earnings on Wednesday
Analysts Set Adicet Bio, Inc. (NASDAQ:ACET) PT at $27.40
See More Headlines
Receive ACET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.

ACET Company Calendar

Last Earnings
3/15/2023
Today
5/31/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Trading Companies & Distributors
Sector
Medical
Current Symbol
NASDAQ:ACET
CUSIP
00444610
CIK
2034
Fax
N/A
Employees
86
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.40
High Stock Price Forecast
$38.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+400.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-69,790,000.00
Pretax Margin
-279.27%

Debt

Sales & Book Value

Annual Sales
$24.99 million
Book Value
$6.20 per share

Miscellaneous

Free Float
30,285,000
Market Cap
$235.42 million
Optionable
Optionable
Beta
2.20

Key Executives

  • Chen SchorChen Schor
    President, CEO, Secretary & Director
  • Brian Nicholas Harvey
    Chief Financial & Accounting Officer
  • Francesco Galimi
    Chief Medical Officer & Senior Vice President
  • Donald Healey
    Chief Technology Officer
  • Blake Aftab
    Chief Scientific Officer & Senior Vice President













ACET Stock - Frequently Asked Questions

Should I buy or sell Adicet Bio stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACET shares.
View ACET analyst ratings
or view top-rated stocks.

What is Adicet Bio's stock price forecast for 2023?

4 analysts have issued 12 month price targets for Adicet Bio's stock. Their ACET share price forecasts range from $19.00 to $38.00. On average, they predict the company's stock price to reach $27.40 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price.
View analysts price targets for ACET
or view top-rated stocks among Wall Street analysts.

How have ACET shares performed in 2023?

Adicet Bio's stock was trading at $8.94 at the beginning of 2023. Since then, ACET shares have decreased by 38.7% and is now trading at $5.48.
View the best growth stocks for 2023 here
.

Are investors shorting Adicet Bio?

Adicet Bio saw a decline in short interest in May. As of May 15th, there was short interest totaling 2,930,000 shares, a decline of 7.6% from the April 30th total of 3,170,000 shares. Based on an average trading volume of 471,600 shares, the short-interest ratio is presently 6.2 days. Approximately 9.8% of the shares of the stock are short sold.
View Adicet Bio's Short Interest
.

When is Adicet Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our ACET earnings forecast
.

How were Adicet Bio's earnings last quarter?

Adicet Bio, Inc. (NASDAQ:ACET) posted its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.16.

What ETFs hold Adicet Bio's stock?
What other stocks do shareholders of Adicet Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include Marin Software (MRIN), FluoroPharma Medical (FPMI), Aurora Cannabis (ACB), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE).

What is Adicet Bio's stock symbol?

Adicet Bio trades on the NASDAQ under the ticker symbol "ACET."

Who are Adicet Bio's major shareholders?

Adicet Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.91%), Carlyle Group Inc. (4.92%), Geode Capital Management LLC (1.41%), State Street Corp (1.31%), Dimensional Fund Advisors LP (1.30%) and Wellington Management Group LLP (1.17%). Insiders that own company stock include Andrew Sinclair, Aya Jakobovits, Blake Aftab, Chen Schor, Don Healey, Francesco Galimi and Jay P Elliott.
View institutional ownership trends
.

How do I buy shares of Adicet Bio?

Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adicet Bio's stock price today?

One share of ACET stock can currently be purchased for approximately $5.48.

How much money does Adicet Bio make?

Adicet Bio (NASDAQ:ACET) has a market capitalization of $235.42 million and generates $24.99 million in revenue each year. The company earns $-69,790,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis.

How can I contact Adicet Bio?

Adicet Bio's mailing address is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. The official website for the company is www.aceto.com. The company can be reached via phone at (650) 503-9095 or via email at jburfening@lhai.com.

This page (NASDAQ:ACET) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -